• 1.

    Coresh J, Astor B, Sarnak MJ. Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. 2004; 13:7381.

  • 2.

    Culleton, BF, et al.. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. 1999; 56:22142219.

  • 3.

    Dries DL, et al.. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35:681689.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Garg, AX, et al.. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002; 61:14861494.

  • 5.

    Go AS, et al.. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:12961305.

  • 6.

    Henry RM, et al.. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62:14021407.

  • 7.

    van Dokkum RP, et al.. Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol 2004; 15:31033110.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Doty JM, et al.. Effect of increased renal venous pressure on renal function. 1999; 4:10001003.

  • 9.

    Malbrain ML, et al.. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions. Intensive Care Med 2006; 32:172232.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Damman K, et al.. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53:5828.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Schlaich MP, et al.. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:9324.

  • 12.

    St John Sutton M, et al.. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997; 96:32949.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Vaziri ND, et al.. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 2003; 63:17985.

  • 14.

    Martin FL, et al.. B-type natriuretic peptide: beyond a diagnostic. Heart Fail Clin 2008; 4:44954.

  • 15.

    Boerrigter G, Lapp H, Burnett JC. Modulation of cGMP in heart failure: a new therapeutic paradigm. Handb Exp Pharmacol 2009; 191:485506.

  • 16.

    Cataliotti A, et al.. Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Heart Fail Clin 2006; 2:26976.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Mohammed SF, et al.. Nesiritide in acute decompensated heart failure: current status and future perspectives. Rev Cardiovasc Med 2008; 9:1518.

  • 18.

    Lisy O, et al.. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 2008; 52:608.

  • 19.

    Lee CY, et al.. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009; 49:66873.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    McKie PM, Sangaralingham SJ, Burnett JC Jr. CD-NP: An Innovative Designer Natriuretic Peptide Activator of Particulate Guanylyl Cyclase Receptors for Cardiorenal Disease. Curr Heart Fail Rep 2010.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Rubattu S, et al.. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21:73341.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Best PJ, et al.. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res 2002; 55:37584.

  • 23.

    Pan S, et al.. Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci USA, 2009; 106:112827.

  • 24.

    Dickey DM, Burnett JC Jr., Potter LR. Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem 2008; 283:350039.

Novel Natriuretic Peptides and the Cardiorenal Syndrome

By Fernando L. Martin
Search for other papers by By Fernando L. Martin in
Current site
Google Scholar
PubMed
Close
and
John C. Burnett Jr.
Search for other papers by John C. Burnett Jr. in
Current site
Google Scholar
PubMed
Close
Restricted access
Save